Here's what you need to know about the M&A mania spreading through big pharma.
News & Analysis: AveXis
Can these red-hot biotech stocks keep the momentum going?
Not only might Biogen be facing a challenger for Spinraza next year, it could be a big challenger with deep pockets.
On a day the market benchmarks closed up, Novartis announced it's buying AveXis and Leucadia National detailed plans to divest some assets and rename itself.
Novartis adds another piece to its emerging gene therapy franchise, sparking a rally across this group of cutting-edge biotechs.
Even risk-averse investors can find exposure to one of the hottest trends in healthcare.
Stellar clinical-trial results have pushed AveXis Inc. stock to an all-time high. Is the stock still a buy at recent prices, or should you wait for a pullback?
Don't be afraid of their lofty share prices. These winners should keep on winning.
AveXis Inc. stock has more than doubled over the past year. Here's why it could climb even further.
Fourth-quarter earnings included a clinical trial update that has Biogen and Ionis Pharmaceuticals investors nervous.